Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool

Background: Danshensu (DSS) possesses unique bioactivity on the cardiovascular system. However, there is a lack of systematical summary of DSS for acute myocardial ischemia injury and no quality assessment tool for the systematical review of cell experiments. Here, we aimed to assess the preclinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Xiao-yi, Zheng, Qun, Tong, Qiang, Zhu, Peng-chong, Zhuang, Zhuang, Zheng, Guo-qing, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297803/
https://www.ncbi.nlm.nih.gov/pubmed/30618743
http://dx.doi.org/10.3389/fphar.2018.01445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297803/
https://www.ncbi.nlm.nih.gov/pubmed/30618743
http://dx.doi.org/10.3389/fphar.2018.01445

Ejemplares similares